Navigation Links
Human Genome Sciences and Xencor Announce Antibody Collaboration
Date:2/7/2008

e antibody structure, including the Fc region to improve potency and half-life and variable region humanization and affinity optimization. We look forward to working with Human Genome Sciences to create novel, best-in-class biotherapeutics that are more effective in treating unmet medical needs while we continue to advance our internal pipeline of XmAb antibody candidates."

About XmAb(TM) Technologies

Xencor's XmAb engineered Fc domains are designed to enhance the therapeutic properties of monoclonal antibodies and can be inserted into antibody candidates against any target antigen to improve one or more important effector functions, including enhanced antibody-mediated tumor cell killing, extended half-life and selective regulation of immune cells. The XmAb(TM) Fv technology generates high-quality human sequence diversity in antibody variable domains in order to improve affinity, stability and production yield.

About Xencor, Inc.

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation(R) technology platform and is a leader in the field of antibody Fc engineering to significantly improve antibody potency and half- life. The company is advancing XmAb(TM) antibody drug candidates optimized for activity against biologically validated targets and its XPro(TM) protein therapeutic candidate into the clinic. Xencor's product development is led by an antibody candidate, XmAb(TM)2513, for the treatment of Hodgkin's disease and T-cell lymphoma, and a protein therapeutic drug candidate, XPro(TM)1595 DN-TNF, for the treatment of inflammatory disease. With multiple partners, such as industry leaders Genentech, Boehringer Ingelheim, Centocor and MedImmune, Xencor is applying its suite of XmAb antibody Fc domains to improve antibody drug candidates for traits such as potency and sustained half-life. For more information, please visit http://www.xencor.com.

A
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... ... next-generation sequencing (NGS) clinical market is poised for huge growth as it prepares to ... its new report that the market drivers of this vibrant industry include increased payor ... as part of a molecular diagnostics trend. , The global market is forecast to ...
(Date:7/1/2015)... CHANDLER, Ariz. , July 1, 2015 ... announced it has earned three Gold, three Silver, and ... Business Awards gala held in Chicago ... recognized as the premier business awards program in the ... and recognizes our company,s strength in developing leaders, cultivating ...
(Date:7/1/2015)... CONNECTICUT (PRWEB) , ... July 01, 2015 , ... ... or sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have an ... medical devices now have an operator control device that will increase healthcare worker ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix Corp. ... common shares of Resverlogix have approved the resolutions ... Capital Limited of 5,600,000 units at a price ... each unit being comprised of one common share ... proceeds of approximately CAD$15 million; and (ii) the ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded ... developed by the Hadassah University Hospital, Israel,s foremost medical ... (92% owned by Hadasit Bio) has completed the recruitment ... I / II clinical trial using its treatment for ...
... (NASDAQ: PRXL ), a leading global biopharmaceutical ... for the Pharmaceutical Industry in The Eighth Annual International ... honoring great performances in business.   PAREXEL was ... efficiency of clinical trials, access emerging markets, and speed ...
... have found a new way to develop straight carbon nanofibers ... for use in novel biomedical research tools, solar cells, water ... grid, and relies on ions to ensure the nanofibers are ... "This is the first time, that I know of, where ...
Cached Biology Technology:Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 2Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 3Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 4PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 2PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 3PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 4PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 5Ions control shape of nanofibers grown on clear substrate 2Ions control shape of nanofibers grown on clear substrate 3
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... and Gail Williams and Stockholm University's Professor Robin Room examined ... and 2002. , Their results were published in the ... Review. , The men were categorised according to ... is a marker for lower socio-economic status (SES). ...
... one-of-a-kind diamond, a unique Picasso or the switch-hitter on ... being rare has biological benefits. Professor Marla Sokolowski, a ... the 1980s discovered that a single gene affects the ... of rarity in populations of fruit flies with two ...
... Baumann, Ph.D., Assistant Investigator, and Nancy Bae, Ph.D., ... published a paper offering insight into the way ... , Published in tomorrow's issue of Molecular Cell, ... End Joining at Human Telomeric DNA Ends" employed ...
Cached Biology News:Double the death rate from cirrhosis for 'blue collar' men 2Survival of the rarest: Fruit flies shed light on the evolution of behavior 2Baumann Lab defines proteins that distinguish chromosome ends from DNA double-strand breaks 2
...
...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
MOUSE ANTI HUMAN MOC31:AZIDE FREE...
Biology Products: